Talis Biomedical welcomes Jeri Hilleman to its Board of Directors

– USA, CA –  Talis Biomedical Corporation (NASDAQ: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the appointment of Jeri Hilleman to its Board of Directors.

Ms. Hilleman will serve as Chair of the Audit Committee.

“We welcome Jeri to our Board and look forward to benefitting from her public company leadership as a chief financial officer and corporate director at multiple life science companies,” said CEO, Brian Coe. “Jeri’s experience and guidance will be instrumental as we continue to scale our business in preparation for the commercial launch of Talis One™.”

About Jeri Hilleman

Jeri Hilleman brings over 20 years of executive leadership and financial experience to Talis. She currently serves as Chairman of the Board of Omada Health and is a Director of Novocure, SI-Bone, and Minerva Neurosciences. Prior to her decision to focus on board responsibilities full time in 2020, Ms. Hilleman served as a Chief Financial Officer for more than 20 years at multiple public companies in the life science industry, including Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies and Cytel.

“Driven by the opportunity to help companies define growth strategies, I look forward to working with the Talis Board and leadership team in their efforts to transform diagnostic testing for infectious diseases at the point-of-care,” said Ms. Hilleman.

Ms. Hilleman graduated from Brown University and earned an MBA from the Wharton School of the University of Pennsylvania. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

About Talis

Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginning with COVID-19. The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California.

For more information: https://talis.bio/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team